title: Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.
abstract: Patients undergoing primary chemotherapy for invasive breast cancer consented to a core biopsy of the invasive breast primary pre- and 24 h postchemotherapy. The resulting tissue was analysed for apoptosis, Ki67, ER and HER-2 using immunohistochemical techniques. These data were then used to evaluate the relationship between these biological markers and response to chemotherapy and overall survival. Response rate to chemotherapy in this group was 86%, 16 patients (25%) achieved a clinical complete response and 41 (63%) a partial response. Prechemotherapy there was a significant correlation between Ki67 and apoptotic index (AI), r=0.6, (P<0.001). A significant rise in AI (P<0.001), and fall in Ki67 (P=0.002) was seen 24 h following chemotherapy. No relationship was seen between pretreatment AI and clinical response, but higher Ki67 and growth index (Ki67/AI ratio, GI) did correlate with clinical response (both r=0.31, P<0.025). No correlation was seen between the change in AI or Ki67 at 24 h and clinical response or survival. Significant changes in apoptosis and proliferation can be demonstrated 24 h following chemotherapy, but these changes do not relate to clinical response or outcome in this study. Pretreatment proliferation and GI are however predictive of response to chemotherapy in breast cancer.
authors.affiliation: Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK. Caroline.Archer@porthosp.nhs.uk
authors.forename: C D
authors.initials: CD
authors.lastname: Archer
authors.forename: M
authors.initials: M
authors.lastname: Parton
authors.forename: I E
authors.initials: IE
authors.lastname: Smith
authors.forename: P A
authors.initials: PA
authors.lastname: Ellis
authors.forename: J
authors.initials: J
authors.lastname: Salter
authors.forename: S
authors.initials: S
authors.lastname: Ashley
authors.forename: G
authors.initials: G
authors.lastname: Gui
authors.forename: N
authors.initials: N
authors.lastname: Sacks
authors.forename: S R
authors.initials: SR
authors.lastname: Ebbs
authors.forename: W
authors.initials: W
authors.lastname: Allum
authors.forename: N
authors.initials: N
authors.lastname: Nasiri
authors.forename: M
authors.initials: M
authors.lastname: Dowsett
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000378:metabolism; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen